Sarcoma

Review Article

Targeting the p53 Pathway in Ewing Sarcoma

Table 5

Chemical structures and proposed mechanisms of small molecule p53 activators.
CompoundMolecular formulaMWTMechanismStage in clinical testing
746939.fig.005aC30H30Cl2N4O4581.5Binds to MDM2 and inhibits p53-MDM2 interactionPhase I
746939.fig.005bC27H32Cl2FN3O4552.5Binds to MDM2 and inhibits p53-MDM2 interactionPhase I
746939.fig.005cC14H12O3S2292.4Binds to p53 and inhibits p53-MDM2 interactionPreclinical
746939.fig.005dC25H34N4O2S454.6SIRT1 and SIRT2 inhibitionPreclinical
746939.fig.005eC62H86N12O161255.5RPL11 and RPL5 releaseClinically approved